Holding pharmaceutical industry actors to account
Our legal, medical, and technical policy experts have collected illustrative case studies where excessive pricing was either challenged (successfully or not) using Intellectual Property, Competition, Human Rights or other Domestic laws, or cases that we closely monitor.
Case studies: Key examples we are monitoring
Below are a list of illustrative examples where we believe that pharmaceutical companies may be abusing market exclusivities to unfairly inflate prices, and which result in patients not being able to afford life-saving medicines.
We categorise these examples into two broad categories. Cases of interest are medicines the Pharmaceutical Accountability Foundation deems worthy of research to determine if their high prices are resulting from unjust practices. Under legal action are medicines where either the Pharmaceutical Accountability Foundation or another public health organisation has found adequate evidence of malfeasance to bring a case against the owning pharmaceutical company.
Current Cases of Interest:
- chenodeoxycholic acid (CDCA Leadiant)
- mexiletine (Namuscla)
- pyrimethamine (Daraprim)
- lithium (Priadel)